Evidence map›Paper›PMID 38880657›Full record

ArticleMolecular oncology2024

The immune response behind peptide vaccination in diffuse midline glioma.

Craig A Vincent, Silvia Remeseiro

Abstract read
In one paragraph

Article in Molecular oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Craig A VincentDepartment of Medical and Translational Biology, Section of Molecular Medicine, Umeå University, Sweden.
Silvia RemeseiroDepartment of Medical and Translational Biology, Section of Molecular Medicine, Umeå University, Sweden.ORCID 0000-0001-5343-007X

Funding

Cancerfonden 21 1720Cancerforskningsfonden i Norrland AMP 19-977Cancerforskningsfonden i Norrland AMP 22-1091Cancerforskningsfonden i Norrland AMP 23-1137Cancerforskningsfonden i Norrland AMP 24-1169Cancerforskningsfonden i Norrland AMP 24-1187Cancerforskningsfonden i Norrland LP 21-2290Cancerforskningsfonden i Norrland LP 24-2378Kempestiftelserna JCSMK23-0199Kempestiftelserna SMK-1964.2Knut och Alice Wallenbergs StiftelseVetenskapsrådet 2019-01960
6 · The paper itself

Abstract

A first-in-human trial demonstrated that a vaccine targeting the histone mutation H3K27M can induce an immune response, in a mutation-specific manner, in patients with diffuse midline glioma. In a recent study by Boschert et al., the same group now dissects the functional immune response triggered after effective vaccination of one of the patients, who has been in remission for over 3 years. The H3K27M peptide vaccine, named H3-vac, induces a CD4

Indexed as

Cancer VaccinesGliomaBrain NeoplasmsHumansVaccinationVaccines, SubunitCancer VaccinesVaccines, Subunitcancerdiffuse midline gliomaH3K27M mutationimmunotherapyneoepitope peptide vaccine

Identifiers

PMID38880657
PMCPMC11306526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.